SGLT2 Inhibitors May Lower Risk of Atopic Dermatitis in Diabetics: Study Dr Riya Dave10 March 2025 10:45 PM ISTResearchers have identified in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT2i) could diminish the risk for the development of...
SGLT2 Inhibitors vs. DPP4 Inhibitors: Study reveals new benefits of SGLT2i for prevention of hypertension Medha Baranwal24 April 2024 10:00 AM ISTJapan: A recent study published in Hypertension Research using nationwide real-world data demonstrated the potential advantage of SGLT2 inhibitors...
EVERGREEN Webinar: Clinical FAQs on T2DM Care, Addressed by Dr V Mohan Dr Jeegar Dattani6 March 2024 12:29 PM ISTThe Evergreen webinar addressed the clinical applicability of Linagliptin and Dapagliflozin in real-world clinical scenarios of type 2 diabetes....
Diabetes medication class tied to lower risk of kidney stones Anshika Mishra3 Feb 2024 9:30 AM ISTRates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones,...
Which new diabetes drugs pose risk of digestive diseases? Medha Baranwal11 April 2023 11:00 AM ISTChina: Glucagon-like peptide 1 receptor agonists (GLP1RAs) should not be given to patients at high risk of certain digestive diseases, whereas...
GLP-1 receptor agonists and SGLT-2 inhibitors reduce COPD exacerbations among diabetes patients Aditi7 Dec 2022 10:45 AM ISTCanada: A recent study published in the BMJ has highlighted that glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose...
SGLT2 inhibitors exhibit enhanced cardioprotective effect in obese or overweight patients Dr Kartikeya Kohli17 Oct 2022 11:00 AM ISTUSA: The cardioprotective effect associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) compared with dipeptidyl peptidase-4 inhibitors...
DPP4i and GLP1Ra as effective as insulin for in-hospital management of diabetes: Study Medha Baranwal12 Aug 2022 12:45 PM ISTColombia: Inpatient management of type 2 diabetes patients in the general ward with GLP1Ra and DPP4i is equally safe and effective compared to insulin...
Drug makers to include DPP4 inhibitors induced Arthralgia in package insert, says CDSCO panel Medical Dialogues Team15 Jan 2022 5:35 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has recommended that CDSCO may...
Treatment with DPP-4i versus sulphonylureas yield similar MACE risk in type 2 diabetics: Study Medha Baranwal20 Dec 2021 9:45 AM ISTUK: Type 2 diabetes (T2D) patients treated with DPP-4 inhibitors versus sulphonylureas as add-on to metformin has a similar risk of cardiovascular...
SGLT2 inhibitors improve survival over DPP4i in patients with cirrhosis and diabetes: Study Medha Baranwal20 July 2021 11:45 AM ISTPatients with cirrhosis needing additional pharmacotherapy for diabetes beyond metformin experience increased survival with SGLT2i in relation to...
SGLT2 Inhibitors tied to lower CV risk relative to DPP-4 Inhibitors in Diabetes: BMJ Dr. Kamal Kant Kohli24 Sept 2020 9:56 AM ISTPrevious trials have shown that SGLT2 inhibitors can reduce the risk of heart conditions such as heart attack, stroke, and heart failure compared with...
